Current status and direct medical cost of amyotrophic lateral sclerosis in the region of Catalonia: A population-based analysis
Open Access
- 11 October 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (10), e0223772
- https://doi.org/10.1371/journal.pone.0223772
Abstract
Amyotrophic lateral sclerosis is a neurodegenerative disease that leads to motor weakness. There is no cure, and treatment focuses on slowing down progression, which is achieved by a multidisciplinary approach. Hence, it is vital to understand the population needs for an optimal management of the disease. To evaluate the current status of amyotrophic lateral sclerosis in the region of Catalonia, how the disease is managed and its direct medical costs. Records corresponding to 841 patients diagnosed between the year 2007 and 2017 were analysed in a retrospective population-based study, including data from primary care centres, hospitals (inpatient and outpatient care), extended care facilities and mental health centres. Mean diagnosis age was 66.11 years (SD = 12.61) and 52.79% of admitted patients were males. On average, 14.91 months elapsed between diagnosis and death, and the mean age of death was 72.64 years (SD = 12.00). Patients were admitted 10.70 times per year, mostly into primary care (86.50%), although most expenses were concentrated in hospital inpatient care. The mean cost per patient per year was €1,168. The 83.24% of patients had more than 4 systems affected by chronic conditions. Primary care is of utmost importance in ALS attention in Catalonia, which may have a direct impact in reducing hospitalisation costs. Nonetheless, the expenses linked to inpatient care represent the biggest portion of total costs. Patients’ healthcare usage patterns and the high proportion of patients with multiple chronic conditions should be taken into account in order to adapt and improve guidelines and healthcare systems.This publication has 18 references indexed in Scilit:
- Genetics of amyotrophic lateral sclerosis: A reviewJournal of the Neurological Sciences, 2019
- Hospital utilization for patients with amyotrophic lateral sclerosis in saskatoon, CanadaAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017
- Amyotrophic lateral sclerosisNature Reviews Disease Primers, 2017
- An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and EuropeAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017
- Care management in amyotrophic lateral sclerosisRevue Neurologique, 2017
- Los grupos de morbilidad ajustados: nuevo agrupador de morbilidad poblacional de utilidad en el ámbito de la atención primariaAtencion Primaria, 2016
- Amyotrophic Lateral Sclerosis in Northern Spain 40 Years Later: What Has Changed?Neurodegenerative Diseases, 2016
- Autoimmune disease preceding amyotrophic lateral sclerosisNeurology, 2013
- Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force ReportValue in Health, 2007
- EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relativesEuropean Journal of Neurology, 2005